Chief Executive Officer, Oak Hill Bio Ltd
Dr. Ali has served as an advisor to Oak Hill Bio since inception. He has public market experience as the Chief Operating Officer and Director of JATT Acquisition Corp, a special acquisition company with a focus on the life science sector. His prior experience also includes serving as Executive Vice President of Translational & Clinical Science at Cambrian Biopharma, a biotech venture capital holding company.
Prior to that, he spent five years at Takeda, where he served as Vice President of Search & Translational Science (Rare Diseases Therapy Area Unit) and also founded and led TAKcelerator™, a virtual rare disease biotech unit within Takeda. Within its first two years, TAKcelerator™ initiated the development of multiple investigational therapies, including drug candidates to treat acute-on-chronic liver disease, CDKL5 Deficiency Disorder (a genetic developmental and seizure disorder), and Stargardt disease (a rare genetic condition causing blindness). Dr. Ali has previously worked with UCB Pharma, Ipsen Group, and Shire Pharmaceuticals.